Company:  DENALI THERAPEUTICS INC. (DNLI)
Form Type:  8-K
Filing Date:  8/6/2019 
CIK:  0001714899 
Address:  161 OYSTER POINT BLVD. 
City, State, Zip:  SOUTH SAN FRANCISCO, California 94080 
Telephone:  (650) 866-8548 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$15.38  
Change: 
0.18 (1.18%)  
Trade Time: 
Oct 11  
Market Cap: 
$1.47B
Trade DNLI now with 

© 2019  
Description of Business
Neurodegeneration represents one of the most significant unmet medical needs of our time, with few effective therapeutic options available for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis ("ALS"), and other neurodegenerative diseases. The burden of these diseases to patients and society is massive. We believe the time is right to make a strong and ambitious effort to defeat neurodegeneration. We believe that we can succeed in a field that has seen limited success in the past, because of our team of experienced and passionately dedicated scientists and drug developers, our focused scientific strategy, and our proprietary blood-brain barrier ("BBB"), platform delivery technology. We are developing a broad portfolio of targeted therapeutic candidates for neurodegenerative diseases and currently have two programs in Phase 1 clinical development.
Register and access this filing in:     
  FORM 8-K
    SECTION 2 FINANCIAL INFORMATION
      Item 2.02 Results of Operations and Financial Condition.
    SIGNATURE
  EXHIBIT 99.1
    INCOME STATEMENT
    BALANCE SHEET